Management of neuronopathic Gaucher disease: A European consensus

[1]  A. Tylki-Szymańska,et al.  Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease. , 2000, Clinical biochemistry.

[2]  C. Harris,et al.  Ocular motor abnormalities in Gaucher disease. , 1999, Neuropediatrics.

[3]  Y. Eto,et al.  Clinical and genetic studies of Japanese homozygotes for the Gaucher disease L444P mutation , 1999, Human Genetics.

[4]  D. Elstein,et al.  Ethical considerations for enzyme replacement therapy in neuronopathic Gaucher disease , 1998, Clinical genetics.

[5]  G. Luc,et al.  Mutation screening of the LDLR gene and ApoB gene in patients with a phenotype of familial hypercholesterolemia and normal values in a functional LDL receptor/apolipoprotein B assay , 1998, Clinical genetics.

[6]  R. Schiffmann,et al.  5 Neuronopathic forms of Gaucher's disease , 1997 .

[7]  G. Addison.  The Metabolic and Molecular Bases of Inherited Disease CD-ROM (Version 1.0) Edited by C.R. Scriver, A.L. Beaudet, W.S. Sly and D. Valle , 1997, Journal of Inherited Metabolic Disease.

[8]  J. Dambrosia,et al.  Prospective study of neurological responses to treatment with macrophage‐targeted glucocerebrosidase in patients with type 3 Gaucher's disease , 1997, Annals of neurology.

[9]  C. Prows,et al.  Gaucher disease: enzyme therapy in the acute neuronopathic variant. , 1997, American journal of medical genetics.

[10]  R. Schiffmann,et al.  Neuronopathic forms of Gaucher's disease. , 1997, Bailliere's clinical haematology.

[11]  A. Tylki-Szymańska,et al.  Types I and III Gaucher Disease in Poland: Incidence of the Most Common Mutations and Phenotypic Manifestations , 1996, European journal of human genetics : EJHG.

[12]  V. Gross‐Tsur,et al.  Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype , 1995, The Lancet.

[13]  K. Bove,et al.  Pathological findings in Gaucher disease type 2 patients following enzyme therapy. , 1995, Human pathology.

[14]  O. Ringdén,et al.  Ten years' experience of bone marrow transplantation for Gaucher disease. , 1995, Transplantation.

[15]  Y. Suzuki,et al.  New Gaucher disease mutations in exon 10: a novel L444R mutation produces a new NciI site the same as L444P. , 1994, Human molecular genetics.

[16]  M. Patterson,et al.  Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher's disease , 1993, Neurology.

[17]  J. Månsson,et al.  Enzyme Replacement Therapy of Infantile Gaucher Disease , 1993, Neuropediatrics.

[18]  N. Conradi,et al.  Rapidly Progressive Type III Gaucher Disease: Deterioration Following Partial Splenectomy , 1990, Acta paediatrica Scandinavica.

[19]  E. Beutler,et al.  PREDICTION OF SEVERITY OF GAUCHER'S DISEASE BY IDENTIFICATION OF MUTATIONS AT DNA LEVEL , 1989, The Lancet.

[20]  A. Erikson.  Gaucher disease‐Norrbottnian type (III) , 1986, Acta paediatrica Scandinavica. Supplement.

[21]  E. Veys,et al.  HL-A AND INFECTIVE SACROILEITIS , 1974 .